Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Harvard Business School
McKesson
Johnson and Johnson
AstraZeneca

Last Updated: August 15, 2022

Details for Patent: 8,268,847


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,268,847 protect, and when does it expire?

Patent 8,268,847 protects OPSUMIT and is included in one NDA.

This patent has thirty-two patent family members in twenty-seven countries.

Summary for Patent: 8,268,847
Title:Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
Abstract: The invention relates to a product containing the compound of formula (I) below ##STR00001## or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved.
Inventor(s): Clozel; Martine (Binningen, CH)
Assignee: Actelion Pharmaceuticals, Ltd. (Allschwil, CH)
Application Number:12/439,290
Patent Claim Types:
see list of patent claims
Use; Compound; Composition;

Drugs Protected by US Patent 8,268,847

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Actelion OPSUMIT macitentan TABLET;ORAL 204410-001 Oct 18, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,268,847

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/IB2006/052999Aug 29, 2006
PCT/IB2006/053857Oct 19, 2006
PCT Information
PCT FiledAugust 28, 2007PCT Application Number:PCT/IB2007/053448
PCT Publication Date:March 06, 2008PCT Publication Number: WO2008/026156

International Family Members for US Patent 8,268,847

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 062501 See Plans and Pricing
Australia 2007290099 See Plans and Pricing
Brazil PI0715698 See Plans and Pricing
Canada 2659770 See Plans and Pricing
Chile 2007002494 See Plans and Pricing
China 101511365 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Mallinckrodt
Johnson and Johnson
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.